nemdx – Nemdx

Redefining Neurodegenerative Disease Studies: Nemdx’s Innovation

Nemdx Inc.’s assays are transforming the study of neurodegenerative diseases. A case study showcases how the company’s technologies, rooted in rational oligonucleotide design, outperform traditional methods. By offering higher affinity, target specificity, and binding options, Nemdx’s assays are redefining disease diagnostics and therapeutics, opening doors to new potential discoveries.

Redefining Neurodegenerative Disease Studies: Nemdx’s Innovation Read More »

Rapid Turnaround in Drug Development: Nemdx’s Impact

Case Studies / nemdx

In the fast-paced world of drug development, Nemdx Inc.’s assays are proving to be game-changers. A case study highlights how Nemdx’s assays enabled researchers to monitor patient responses to therapies and make informed decisions within days to weeks. This swift turnaround not only expedites the research journey but also contributes to more efficient drug development.

Rapid Turnaround in Drug Development: Nemdx’s Impact Read More »

Uncovering ALS Biomarkers: Nemdx’s Collaborative Approach

Case Studies / nemdx

Nemdx Inc.’s collaboration with leading research centers has yielded remarkable insights into ALS biomarkers. By utilizing their proprietary assays, researchers were able to identify potential biomarker candidates associated with both sporadic and familial ALS. These findings are paving the way for more targeted therapies and improved ALS patient care.

Uncovering ALS Biomarkers: Nemdx’s Collaborative Approach Read More »

Versatile Assays Revolutionizing Pharmaceutical Research

News / nemdx

In the realm of pharmaceutical research, Nemdx Inc.’s assays are making a significant impact. With applications ranging from neurodegenerative diseases to cancer mutations, these assays offer unparalleled sensitivity and specificity. Researchers are praising the company’s commitment to delivering valuable information without excessive costs, enhancing drug development and validation efforts.

Versatile Assays Revolutionizing Pharmaceutical Research Read More »

Revolutionizing Pharmaceutical Research

Case Studies / nemdx

Revolutionizing Pharmaceutical Research Read More »

ALS Finding a Cure and The ALS Association Partner to Reduce Time to Initial ALS Diagnosis

Press Releases / nemdx

Organizations Commit $2M towards New International ALS Diagnostics Effort Boston, MA., Washington, D.C., and Palm Beach, FL (August 16, 2023) — ALS Finding a Cure® (ALSFAC) and The ALS Association have awarded seven new grants worth a total of $2 million to support the development of early diagnostics for ALS. More than 150 years after the

ALS Finding a Cure and The ALS Association Partner to Reduce Time to Initial ALS Diagnosis Read More »

Nemdx’s Breakthrough in ALS Detection Garnering Attention

Case Studies, News / nemdx

Nemdx Inc.’s pioneering work in early ALS detection is garnering attention in the medical community. By collaborating with leading research centers, the company’s innovative assays are shedding light on potential biomarker candidates associated with ALS. This breakthrough holds promise for more accurate diagnosis and targeted therapies for ALS patients.

Nemdx’s Breakthrough in ALS Detection Garnering Attention Read More »

Nemdx Empowers Pharma Industry with Next-Generation Diagnostic Tools

Press Releases / nemdx

Nemdx Inc. is reshaping the landscape of drug and biomarker development with its rational approach. The company’s assays offer high accuracy and precision in detecting disease markers and biomolecules, enabling researchers to monitor patient responses to therapies and make informed adjustments. Nemdx’s multiplexing capabilities and seamless integration into drug development pipelines provide a comprehensive view

Nemdx Empowers Pharma Industry with Next-Generation Diagnostic Tools Read More »

ALS Finding a Cure (ALSFAC) has awarded a $400,000 grant to Nemdx Inc. (Nemdx)

1 Comment / Press Releases / nemdx

Boston- ALS Finding a Cure® (ALSFAC) has awarded a $400,000 grant to a team of researchers from Massachusetts General Hospital (MGH), a Boston based private entity Nemdx Inc. (Nemdx), and the International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy, for their project “Developing a Comprehensive Blood Test for Sporadic and Familial ALS.” Dr.

ALS Finding a Cure (ALSFAC) has awarded a $400,000 grant to Nemdx Inc. (Nemdx) Read More »

Author name: nemdx